The Results for Tomorrow's Election Are Not Final -- but Regardless of the Result, the DATATRAK Board Is Committed to Working Cooperatively and Constructively for the Benefit of All Shareholders; Board Calls on Arosa to Honor Its Commitment to Do the Same and Immediately Cease Its Attacks on the Company, Management and the Board, and Work Together to Repair the Damage to the Company Done by This Proxy Contest; in That Light, the Board Calls on Arosa to Join With the Company in Resolving the Litigation Between the Parties

/EINPresswire.com/ -- CLEVELAND, OH--(Marketwired - January 07, 2016) - DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical™ technologies and delivering related services for the clinical trials industry, today released a statement from its three Class II Directors who will remain in office regardless of the results of tomorrow's Annual Meeting of Shareholders.

Dr. Jerry Kaiser, currently the Company's Lead Independent Director, said, "We have made our case to the shareholders about why we believe the Company's management team and Board is best positioned to see the Company's strategic plan through to fruition. We do not yet know the final results for tomorrow's Annual Meeting, but regardless of whether the Company's slate or Arosa's prevails and despite our concerns about the tactics used by Arosa and its allies in this contest and the damage it has done to the Company's business and stakeholders, we are all completely committed to cooperating and working constructively with Arosa for the benefit of all shareholders." The Class II Directors made the following additional commentary on working constructively with Arosa going forward, if Arosa and their candidates prevail in tomorrow's election:

• We are committed to collaborating with Arosa, listening to their detailed plans for the business, and working together to repair the damage to the business caused by this proxy contest in order to reignite the positive momentum that has been in many ways interrupted by this fight.

• We call on Arosa and its allies to honor its commitment to working cooperatively with the Company's employees, management team and the Board.

• We call on Arosa to immediately stop the personal attacks on members of our management team, and to take the lead in alleviating the toxic atmosphere around this proxy contest that is causing damage to our business and creating a sense of great concern for a number of employees and customers. We also call on Arosa to reign in the activities of certain allies associated with its campaign who have been aggressively targeting members of our management team and Board, including, for example, making harassing phone calls and reaching out to individuals and institutions in no way associated with the Company's business.

• In light of our desire to put all of this activity behind us, we also call on Arosa to join with us in quickly resolving all outstanding litigation between the parties in this matter. Despite our belief in the merits of our action, we recognize that continuing this litigation will remain a significant distraction and burden on all parties and will make constructive engagement going forward nearly impossible while such litigation overhangs the relationship between the parties.

• Beginning today, and no matter the outcome at tomorrow's Annual Meeting of Shareholders, let all parties to this situation put all of our collective energies to growing the Company's business, utilizing the Company's excellent technology platform and talented employees, and putting all of this negative conflict behind us.

About  DATATRAK

DATATRAK International is a worldwide technology and services Company delivering Unified dClinical™ solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Chicago, IL; Cary Research Triangle Park (RTP), North Carolina; Bryan, Texas; and Cleveland, Ohio. For more information, visit http://www.datatrak.com.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on March 13, 2015 announcing its results for the full year period ended December 31, 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

Investor Relations Contacts:
Chris Hodges or Nick Hughes
Alpha IR Group
DTRK@alpha-ir.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.